drugset
Drugs / PF-06865571
last change Jan 2026 re-read 9 days ago

PF-06865571

also known as ervogastat

Small molecule targets DGAT2 via inhibition

Developed for
NAFLD1 · metabolic dysfunction-associated steatohepatitis
Investigated by
Pfizer

Trials 13

today NCT04866225 · Ph 1 NCT04839393 · Ph 1 NCT04399538 · Ph 2 NCT04321031 · Ph 2 NCT04091061 · Ph 1 NCT04044053 · Ph 1 NCT03776175 · Ph 2 NCT03593707 · Ph 1 NCT03513588 · Ph 1 NCT03534648 · Ph 1 NCT03372044 · Ph 1 NCT03230383 · Ph 1 NCT03092232 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 110 trials · 1 met primary
Phase 1 NCT04866225 May → Jul 2021 — Pfizer Completed No outcome recorded
Phase 1 NCT04839393 Apr → Oct 2021 — Pfizer Completed No outcome recorded
Phase 1 NCT04091061 Oct 2019 → Apr 2020 — Pfizer Completed No outcome recorded
Phase 1 NCT04044053 Aug → Oct 2019 — Pfizer Completed No outcome recorded
Phase 1 NCT03593707 Aug 2018 → Jan 2019 — Pfizer Completed No outcome recorded
Phase 1 NCT03513588 Jun 2018 → Mar 2019 NAFLD1, metabolic dysfunction-associated steatohepatitis Pfizer Completed Met primary
Phase 1 NCT03534648 Apr → Jul 2018 — Pfizer Completed No outcome recorded
Phase 1 NCT03372044 Jan → Mar 2018 — Pfizer Completed No outcome recorded
Phase 1 NCT03230383 Aug 2017 → May 2018 — Pfizer Completed No outcome recorded
Phase 1 NCT03092232 Mar → Jul 2017 — Pfizer Completed No outcome recorded
Phase 23 trials · 2 met primary
Phase 2 NCT04399538 Aug 2020 → Mar 2022 NAFLD1, metabolic dysfunction-associated steatohepatitis Pfizer Completed Met primary
Phase 2 NCT04321031 Jun 2020 → Jan 2024 NAFLD1, metabolic dysfunction-associated steatohepatitis Pfizer Completed No outcome recorded
Phase 2 NCT03776175 Jan → Sep 2019 NAFLD1 Pfizer Completed Met primary

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2022-05-26 Pfizer Regulatory Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH) pfizer.com ↗
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as PF-06865571 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04044053 ↗
12

NCT03230383 ↗

NCT03534648 ↗

NCT03092232 ↗

NCT03593707 ↗

NCT03776175 ↗

NCT03372044 ↗

NCT03513588 ↗

NCT04839393 ↗

NCT04321031 ↗

NCT04399538 ↗

Show 2 more sources
Known as ervogastat “diacylglycerol acyltransferase 2 inhibitor (DGAT2i, PF-06865571, ervogastat)” PMID 35354614 ↗ Mar 2022
1

“DGAT2i ervogastat (PF-06865571)” PMID 36690550 ↗ Jan 2023
Action Inhibit “DGAT2 inhibitor (DGAT2i)” PMID 36690550 ↗ Jan 2023
Modality Small molecule “Small molecule inhibitors of the terminal step in intrahepatic triglyceride synthesis (diacylglycerol acyltransferase 2 inhibitor (DGAT2i, PF-06865571, ervogastat))” PMID 35354614 ↗ Mar 2022
Route Oral “Single Escalating Oral Doses Of Pf-06865571” NCT03092232 ↗
Target DGAT2 “DGAT2 inhibitor (DGAT2i)” PMID 36690550 ↗ Jan 2023